Sector: Medical Devices - Therapeutic Devices
Medical Field: Cardiovascular
Technological Field: Cardiovascular
Year Established: 1992
Medinol is dedicated to the science of cardiovascular intervention. In the past 20 years, we have delivered over two million coronary stents to patients worldwide. Our products constantly stretch the limits of innovation and our cutting-edge technology continues to demonstrate extraordinary clinical results. And all our products are manufactured in-house, leveraging the proprietary QualitySurface manufacturing technology that ensures consistently exceptional product quality and safety.
Medinol develops, manufactures, and markets the industry-leading NIRxcell™ Bare Metal Stent (BMS). Made from thin cobalt-chrome alloy and recognized for its unique flexibility, conformability, and scaffolding, NIRxcell has a dramatically lower rate of restenosis (blood vessel re-narrowing) compared to competing stents in a recent clinical study.
Currently in clinical trials, NIRsupreme is Medinol’s new generation drug eluting stent (DES). NIRsupreme is the first elastomer based DES (eDES) and it sets new standards for coating quality, integrity and resistance to crack and peel. The NIRsupreme eDES is being investigated in two clinical trials with over 2,200 patients and designed for regulatory approvals in the United States and Europe.
Founded in 1992 by Dr. Judith Richter and Dr. Jacob (Kobi) Richter and privately held to this day, Medinol continues to benefit from the leadership and insight of its founders. With 300 employees on board, we proudly maintain our family spirit and entrepreneurial culture. Our diverse and multidisciplinary research team boasts broad experience in physics, engineering, chemistry, biology, materials, pharmaceutics and more. Together, we constitute a creative, caring and motivated industry-leading force.